FDA Recall D-0355-2019

Lupin Pharmaceuticals Inc. · Baltimore, MD

Class I — life-threatening Terminated 607 days on record

Highest impact — Class I recall — FDA determination of strong likelihood of serious adverse health consequence or death.

Product

Ceftriaxone for Injection USP, 250 mg, packaged in a) one Single Use Vial (NDC 68180-611-01) and b) 10 Single Use Vials per box (NDC 68180-611-10); Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., 111 South Calvert Street, Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Mandideep 462 046 INDIA.

Lot / code: Lot #: a) C600142, Exp 08/19; b) C600136, Exp 08/19; C600182, Exp 09/19, C700147, Exp 05/20; C700207, Exp 09/20 Additional lots added 12/19/2018 - C600142, C700147 and C700207

Quantity: a) 12,000 vials; b) 11,763 boxes

Reason for recall

Presence of Particulate Matter: Product complaints received of grey flecks, identified as shredded rubber particulate matter from the stopper observed in reconstituted vials.

Recall record

Recall number: D-0355-2019
Classification: Class I
Status: Terminated
Voluntary or mandated: Voluntary: Firm initiated
Firm notification: Letter
Distribution: Nationwide in the USA and Puerto Rico.
Recall initiated: 2018-12-20
Classified by FDA Center: 2019-01-14
FDA published: 2019-01-16
Terminated: 2020-08-18
Recalling firm: Lupin Pharmaceuticals Inc.
Firm location: Baltimore, MD

‹ All recalls